Next-generation paclitaxel-nanoparticle formulation for pancreatic cancer treatment

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Pancreatic cancer (PanCa) has a high mortality rate due to limited treatment options.
• The dense tumor microenvironment in PanCa hinders effective drug delivery.
• Novel nanoparticle systems are needed to improve therapeutic payload delivery for PanCa.

Purpose of the Study:

• To develop and evaluate a next-generation nanoparticle formulation for pancreatic cancer treatment.
• To assess the efficacy of the developed nanoparticles in preclinical models of PanCa.

Main Methods:

• A multi-layered nanoparticle formulation (PPNPs) was created using paclitaxel-loaded poly(lactic-co-glycolic acid) coated with Pluronic F127, polyvinyl alcohol, and poly-L-lysine.
• Nanoparticle characterization included size, Zeta potential, and cellular uptake mechanisms (lipid raft mediated).
• In vitro and in vivo efficacy was evaluated in orthotopic xenograft mouse models (chemo-naïve and chemo-exposed), including nanomechanical analysis and immunohistochemistry.

Main Results:

• PPNPs demonstrated optimal size (~160 nm) and negative Zeta potential (-6.02 mV).
• Efficient cellular internalization and significant inhibition of PanCa growth and metastasis were observed in vitro and in vivo.
• Treatment with PPNPs altered cancer cell nanomechanical properties and reduced key protein markers (ki67, vimentin, slug) in tumors.

Conclusions:

• PPNPs show potential as a robust platform for pancreatic cancer therapy.
• The nanoparticle system effectively overcomes drug delivery barriers in desmoplastic pancreatic tumors.
• Further development of PPNPs could lead to improved treatment outcomes for pancreatic cancer patients.